# EDGAR Filing Document

**Accession Number:** 0001423603
**File Stem:** 0001423603-26-000008
**Filing Date:** 2026-4
**Character Count:** 14298
**Document Hash:** 65e83cfd4f0cda72dff8825d23b53848
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001423603-26-000008.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001423603-26-000008

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Longevity Health Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001842939
- **STANDARD INDUSTRIAL CLASSIFICATION:** SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 861645738
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92731
- **FILM NUMBER:** 26849682

**BUSINESS ADDRESS:**
- **STREET 1:** 2403 SIDNEY STREET, SUITE 300
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203
- **BUSINESS PHONE:** 412-894-8248

**MAIL ADDRESS:**
- **STREET 1:** 2403 SIDNEY STREET, SUITE 300
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carmell Corp
- **DATE OF NAME CHANGE:** 20230801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Carmell Therapeutics Corp
- **DATE OF NAME CHANGE:** 20230727

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALPHA HEALTHCARE ACQUISITION CORP III
- **DATE OF NAME CHANGE:** 20210127
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ajjarapu J. Ram
- **CENTRAL INDEX KEY:** 0001423603

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 2533 WINDGUARD CIRCLE
- **STREET 2:** SUITE 101
- **CITY:** WESLEY CHAPEL
- **STATE:** FL
- **ZIP:** 33544

## Ex-1

```

Exhibit 1

Schedule 13D Joint Filing Agreement

In accordance with the requirements of Rule 13d-1(k) under the Securities
Exchange Act of 1934, as amended, and subject to the limitations set forth
therein, the parties set forth below agree to jointly file the Schedule 13D
to which this Joint Filing Agreement is attached and have duly executed this
Joint Filing Agreement as of the date set forth below.

Dated: April 8, 2026

							/s/ Janakiram Ajjarapu
							Janakiram Ajjarapu

							INTERNATIONAL CAPITAL PARTNERS LLC

							By:	/s/ Janakiram Ajjarapu
							Name:	Janakiram Ajjarapu
							Title:	Managing Member

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Longevity Health Holdings, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Bryan J. Cassaday**<br>2403 Sidney Street, Suite 300<br>Pittsburgh PA 15203<br>281-297-8276

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/16/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ajjarapu J. Ram** | Name of reporting person<br>**Ajjarapu J. Ram** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**689656.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**689656.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**689656.00** | Aggregate amount beneficially owned by each reporting person<br>**689656.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.9%** | Percent of class represented by amount in Row (11)<br>**27.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note to Row 13: The percentages reported in this Schedule 13D are based on 2,475,321 shares of common stock, $0.0001 par value per share (the "Common Stock"), of Longevity Health Holdings, Inc. (the "Issuer") outstanding as of March 16, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**International Capital Partners LLC** | Name of reporting person<br>**International Capital Partners LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**FLORIDA** | Citizenship or place of organization<br>**FLORIDA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**689656.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**689656.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**689656.00** | Aggregate amount beneficially owned by each reporting person<br>**689656.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.9%** | Percent of class represented by amount in Row (11)<br>**27.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Note to Row 13: The percentages reported in this Schedule 13D are based on 2,475,321 shares of Common Stock outstanding as of March 16, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Longevity Health Holdings, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2403 SIDNEY STREET, SUITE 300, PITTSBURGH, PA, 15203

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the Common Stock reported herein for investment purposes and to facilitate a change in the leadership of the Issuer.

On March 13, 2026, ICP entered into a Common Stock Purchase Agreement (the "Stock Purchase Agreement") with the Issuer. Pursuant to the Stock Purchase Agreement, ICP purchased 689,656 shares of Common Stock (the "Shares") at a purchase price of $0.29 per share, for an aggregate purchase price of $200,000.24. Mr. Ajjarapu, as the managing member of ICP, may be deemed to have shared voting and dispositive power over these shares.

The acquisition of the Shares was made in connection with a planned transition of the Issuer's leadership. Effective as of March 16, 2026, Mr. Ajjarapu was appointed by the Issuer's Board of Directors (the "Board") as the Chief Executive Officer of the Issuer, a Class III director and the Chairman of the Board.

The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. In addition, the Reporting Person, in his capacity as Chief Executive Officer and Chairman of the Board, may engage in discussions with management, the Board, other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as security offerings and/or share repurchases by the Issuer; sales or acquisitions of assets or businesses; changes to the capitalization of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board.

Except as set forth herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by the Reporting Persons.

**(b)**
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which the Reporting Persons have the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
Except as reported on this Schedule 13D, neither of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 3 and 4 of this Schedule 13D is incorporated by reference herein.

Stock Purchase Agreement

On March 13, 2026, the Issuer and ICP entered into the Stock Purchase Agreement, pursuant to which ICP purchased the Shares. The Stock Purchase Agreement contains customary representations, warranties, and covenants of the Issuer and ICP.

Registration Rights

Pursuant to the Stock Purchase Agreement, the Issuer is obligated to file a resale registration statement (the "Resale Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") no later than 60 calendar days after March 16, 2026. The Issuer has agreed to use its best efforts to cause such Resale Registration Statement to be declared effective to cover the resale of all of the Shares.

Indemnification and Restrictive Covenants

In connection with his appointment as Chief Executive Officer and Chairman of the Board, Mr. Ajjarapu executed the Issuer's standard form of indemnity agreement and a restrictive covenants agreement for officers. Under the Stock Purchase Agreement, the Issuer has also agreed to indemnify ICP and its affiliates against certain claims, damages, and expenses arising out of the agreement, except in cases of bad faith, actual fraud, gross negligence, or willful misconduct.

Management Appointments

In connection with the Stock Purchase Agreement, the Board appointed Mr. Ajjarapu as Chief Executive Officer, a Class III director, and Chairman of the Board, effective March 16, 2026. Other than the Stock Purchase Agreement, there are no arrangements or understandings between Mr. Ajjarapu and any other person pursuant to which he was selected as an officer or director.

Other Relationships

Mr. Ajjarapu is the managing member of, and holds a direct minority membership interest in, ICP. He also serves as the trustee of a family trust that holds the remaining outstanding membership interests in ICP.

Except as described above or as set forth in the exhibits to this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Persons and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ajjarapu J. Ram

**Signature:** /s/ Janakiram Ajjarapu

**Name/Title:** Janakiram Ajjarapu

**Date:** 04/08/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** International Capital Partners LLC

**Signature:** /s/ Janakiram Ajjarapu

**Name/Title:** Janakiram Ajjarapu, Managing Member

**Date:** 04/08/2026